Literature DB >> 16569439

An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development.

Susan E Witko1, Cheryl S Kotash, Rebecca M Nowak, J Erik Johnson, Lee Anne C Boutilier, Krista J Melville, Sannyu G Heron, David K Clarke, Aaron S Abramovitz, R Michael Hendry, Mohinder S Sidhu, Stephen A Udem, Christopher L Parks.   

Abstract

Recovery of recombinant, negative-strand, nonsegmented RNA viruses from a genomic cDNA clone requires a rescue system that promotes de novo assembly of a functional ribonucleoprotein (RNP) complex in the cell cytoplasm. This is accomplished typically by cotransfecting permissive cells with multiple plasmids that encode the positive-sense genomic RNA, the nucleocapsid protein (N or NP), and the two subunits of the viral RNA-dependent RNA polymerase (L and P). The transfected plasmids are transcribed in the cell cytoplasm by phage T7 RNA polymerase (T7 RNAP), which usually is supplied by infection with a recombinant vaccinia virus or through use of a stable cell line that expresses the polymerase. Although both methods of providing T7 RNAP are effective neither is ideal for viral vaccine development for a number of reasons. Therefore, it was necessary to modify existing technology to make it possible to routinely rescue a variety of recombinant viruses when T7 RNAP was provided by a cotransfected expression plasmid. Development of a broadly applicable procedure required optimization of the helper-virus-free methodology, which resulted in several modifications that improved rescue efficiency such as inclusion of plasmids encoding viral glycoproteins and matrix protein, heat shock treatment, and use of electroporation. The combined effect of these enhancements produced several important benefits including: (1) a helper-virus-free methodology capable of rescuing a diverse variety of paramyxoviruses and recombinant vesicular stomatitis virus (rVSV); (2) methodology that functioned effectively when using Vero cells, a suitable substrate for vaccine production; and (3) a method that enabled rescue of highly attenuated recombinant viruses, which had proven refractory to rescue using published procedures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569439     DOI: 10.1016/j.jviromet.2006.02.006

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  33 in total

1.  Anterograde or Retrograde Transsynaptic Circuit Tracing in Vertebrates with Vesicular Stomatitis Virus Vectors.

Authors:  Kevin T Beier; Nathan A Mundell; Y Albert Pan; Constance L Cepko
Journal:  Curr Protoc Neurosci       Date:  2016-01-04

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  The L gene of J paramyxovirus plays a critical role in viral pathogenesis.

Authors:  Zhuo Li; Jie Xu; Zhenhai Chen; Xiudan Gao; Lin-Fa Wang; Christopher Basler; Kaori Sakamoto; Biao He
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

6.  Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Authors:  Demetrius Matassov; Chad E Mire; Theresa Latham; Joan B Geisbert; Rong Xu; Ayuko Ota-Setlik; Krystle N Agans; Dean J Kobs; Morgan Q S Wendling; Amanda Burnaugh; Thomas L Rudge; Carol L Sabourin; Michael A Egan; David K Clarke; Thomas W Geisbert; John H Eldridge
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

7.  Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

8.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

9.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.